What Drugs Should You Not Take With Empagliflozin? A Complete Interaction Guide

Empagliflozin carries major interactions with insulin and sulfonylureas that substantially increase hypoglycemia risk and typically require dose reduction of the glucose-lowering agent. Additionally, moderate interactions with diuretics, lithium, and certain cardiovascular medications warrant careful monitoring of volume status, electrolytes, and renal function. Healthcare providers must proactively screen for these combinations and establish clear monitoring protocols to prevent serious adverse events.

What Empagliflozin Is and How It Works

Empagliflozin (marketed as Jardiance) is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used to reduce blood glucose in patients with type 2 diabetes mellitus and to reduce cardiovascular and renal mortality in patients with type 2 diabetes and established cardiovascular disease or diabetic kidney disease. It works by blocking SGLT2 proteins in the proximal convoluted tubule of the nephron, preventing reabsorption of glucose filtered by the glomerulus, thereby increasing urinary glucose excretion (glycosuria) independent of insulin secretion.

The pharmacological profile of empagliflozin explains why certain drug interactions occur. Because it acts directly on renal tubular transport rather than on insulin secretion or hepatic glucose metabolism, empagliflozin is additive with other insulin secretagogues and insulin itself—resulting in compounded hypoglycemic effects. Similarly, because it increases urinary volume and sodium losses, it amplifies the diuretic effect of medications like furosemide, hydrochlorothiazide, and bumetanide, raising the risk of hypovolemia and prerenal acute kidney injury. Empagliflozin undergoes minimal hepatic metabolism (approximately 46% unchanged renal excretion, 54% metabolism by glucuronidation via UGT1A9 and minor CYP3A4 pathways), meaning it has relatively few metabolic drug interactions but substantial renal and osmotic effects that drive clinically relevant interactions.

Most Serious Interactions: Hypoglycemia Risk With Insulin and Sulfonylureas

Insulin and Empagliflozin (Major Interaction)

The combination of empagliflozin with insulin carries a black-box warning risk for severe hypoglycemia. The mechanism is purely pharmacodynamic: empagliflozin lowers blood glucose via increased urinary excretion; insulin lowers blood glucose by suppressing hepatic glucose output and promoting peripheral glucose uptake. These two mechanisms are additive, and hypoglycemia can occur at any time—not just during fasting or immediately postprandial. The risk is particularly acute in patients with reduced renal function (eGFR <30 mL/min/1.73m²), dehydration, or caloric restriction, all of which lower the renal glucose threshold further.

FDA labeling recommends that insulin doses be reduced by 10–25% when empagliflozin is initiated, with further titration based on blood glucose monitoring. Patients on insulin pumps require individualized assessment; basal rates and bolus ratios should be reviewed by an endocrinologist or certified diabetes educator. Home glucose monitoring should increase in frequency to at least four times daily (fasting, premeal, postmeal, bedtime) during the first 2 weeks of combination therapy. Patients must be counseled on hypoglycemia recognition (tremor, palpitations, diaphoresis, confusion) and rescue with 15 grams of fast-acting carbohydrate.

Sulfonylureas and Empagliflozin (Major Interaction)

Sulfonylureas (glyburide, glipizide, glimepiride) stimulate pancreatic beta-cell insulin secretion in a glucose-independent manner. Combined with empagliflozin, this creates sustained insulin elevation paired with enhanced urinary glucose wasting—a synergy that produces profound hypoglycemia risk. Sulfonylureas also carry inherent hypoglycemia risk as monotherapy, particularly in elderly patients and those with hepatic or renal impairment. The addition of empagliflozin exacerbates this risk.

Clinical guidance: Consider deprescribing sulfonylureas in favor of metformin monotherapy or a DPP-4 inhibitor when initiating empagliflozin. If sulfonylureas must be continued, reduce the dose by 25–50% at empagliflozin initiation. Glimepiride and glipizide dosing is more easily titrated than glyburide (which has longer duration and narrower therapeutic window). Establish a glucose monitoring schedule: home capillary testing before meals and at bedtime, with HbA1c reassessment at 3 months. If hypoglycemic episodes occur, immediate dose reduction or deprescribing is warranted.

Moderate Interactions: Volume Depletion, Lithium Toxicity, and Renal Function

Diuretics and Empagliflozin (Moderate Interaction—Additive Diuretic Effect)

Empagliflozin inherently causes osmotic diuresis: the filtered glucose in the proximal tubule exerts osmotic pressure, preventing water reabsorption and increasing urine volume by 10–30%. When combined with loop diuretics (furosemide, bumetanide, torsemide) or thiazide diuretics (hydrochlorothiazide, chlorthalidone), the result is compounded urinary volume loss. This interaction is particularly problematic in heart failure patients receiving high-dose loop diuretics for decompensation, and in elderly patients with borderline renal perfusion.

Mechanisms of harm include intravascular volume depletion leading to prerenal acute kidney injury, hypernatremia (due to hypotonic fluid loss exceeding sodium loss), orthostatic hypotension, syncope, and acute decompensated heart failure paradoxically worsened by volume loss. Patients on ACE inhibitors or angiotensin receptor blockers are at added risk because these agents depend on adequate glomerular filtration pressure—volume depletion can reduce eGFR acutely.

Monitoring parameters: Baseline serum creatinine, eGFR, sodium, and potassium before empagliflozin initiation. Repeat labs at 1–2 weeks after initiation, then quarterly. Assess orthostatic vital signs at each visit. Counsel patients to report dizziness, syncope, or polyuria. In heart failure patients, loop diuretic doses may need reduction as empagliflozin is titrated up. Patients with eGFR <20 mL/min/1.73m² should not receive empagliflozin (dose-dependent: empagliflozin 10 mg requires eGFR ≥20; empagliflozin 25 mg requires eGFR ≥25).

Lithium and Empagliflozin (Moderate Interaction—Altered Clearance)

Lithium is filtered by the glomerulus and reabsorbed in the proximal convoluted tubule via sodium-lithium exchange (where SGLT2 also resides). SGLT2 inhibitors increase urinary sodium and glucose losses, which can alter the sodium-lithium exchange dynamics and potentially increase lithium clearance, lowering serum concentrations. However, the clinical evidence is somewhat paradoxical: some reports show decreased lithium levels, while dehydration from empagliflozin-induced diuresis can conversely concentrate lithium. The net effect is unpredictable.

Clinical management: If empagliflozin must be used in a lithium-treated patient (typically for bipolar disorder or mood stabilization), baseline lithium level should be obtained and checked again at 1 week post-initiation, then every 2 weeks for 8 weeks. Target lithium levels are typically 0.6–1.2 mEq/L for maintenance. Renal function (eGFR) and volume status should be monitored closely. Teach the patient to maintain consistent sodium and fluid intake (neither dehydration nor volume overload). Many clinicians prefer switching from lithium to valproate or lamotrigine in patients requiring empagliflozin, given the complexity of monitoring.

ACE Inhibitors, Angiotensin Receptor Blockers, and Empagliflozin

While not listed as a formal FDA drug interaction, the combination of empagliflozin with ACE inhibitors (lisinopril, enalapril) or ARBs (losartan, valsartan) increases the risk of hyperkalemia paradoxically, despite empagliflozin's generally modest potassium-lowering effect. The mechanism involves reduced glomerular filtration pressure from combined vasodilation, which can impair potassium secretion in the distal tubule. Additionally, prerenal azotemia from volume depletion can elevate potassium further.

Monitor serum potassium and creatinine at baseline, 1–2 weeks post-initiation, and quarterly thereafter. Avoid empagliflozin in patients with baseline potassium >5.5 mEq/L or eGFR <20 mL/min/1.73m².

Clinical Scenario 1: Elderly Patient With Heart Failure and Type 2 Diabetes on Multiple Diuretics

An 72-year-old male with a history of heart failure with reduced ejection fraction (HFrEF, EF 35%), hypertension, and type 2 diabetes mellitus is hospitalized for acute decompensated heart failure. His medications include furosemide 80 mg daily, lisinopril 20 mg daily, metoprolol 50 mg twice daily, spironolactone 25 mg daily, and metformin 1000 mg twice daily. His HbA1c is 7.9%, eGFR is 52 mL/min/1.73m², and potassium is 4.8 mEq/L. His cardiologist recommends initiating empagliflozin 10 mg daily for both glucose control and heart failure mortality reduction.

Interaction Management: The clinician must weigh the mortality benefit of empagliflozin in heart failure against the additive diuretic effect. After discharge, the patient should start empagliflozin at 10 mg daily with careful discharge instructions: no dose reduction of furosemide initially, but patient education on orthostatic precautions and daily weights (call if >2–3 lb gain in 1 day or >5 lb in 1 week—these may indicate inadequate diuresis or volume shifts, not heart failure progression). Labs should be rechecked 7–10 days post-discharge: serum creatinine (assess for prerenal AKI), potassium, and sodium. If eGFR drops >15% from baseline, empagliflozin should be held until renal function stabilizes. If potassium rises above 5.5 mEq/L, spironolactone dose may need reduction. Lisinopril can be continued if renal function and potassium remain stable. Furosemide dose may actually be reduced if volume status improves. The patient should follow up in-person with cardiology within 2 weeks and primary care within 1 week of discharge.

Clinical Scenario 2: Patient With Type 2 Diabetes Requiring Insulin Initiation Concurrent With Empagliflozin

A 58-year-old female with a BMI of 32 kg/m², newly diagnosed type 2 diabetes, and baseline HbA1c of 11.2% is started on metformin 1500 mg daily and empagliflozin 10 mg daily. At 3 months, her HbA1c is 8.1% but fasting glucose remains 180–220 mg/dL, indicating need for basal insulin. Her endocrinologist initiates insulin glargine 10 units at bedtime with instructions to titrate by 2 units weekly until fasting glucose is 100–130 mg/dL.

Interaction Management: Given the major interaction between empagliflozin and insulin, the endocrinologist counsels the patient extensively on hypoglycemia risk. Instead of the standard 10 units, insulin glargine is started at 8 units at bedtime. The patient is prescribed a home glucose meter and test strips with instructions to check fasting glucose daily and to perform additional testing (mid-morning, lunch, before dinner, bedtime) for the first 2 weeks. She is given a glucagon emergency kit and trained on self-injection technique. Her partner or family member is also instructed on glucagon administration and hypoglycemia recognition. A diabetes educator reviews carbohydrate counting and the insulin-to-carbohydrate ratio. Follow-up is scheduled for 2 weeks via phone (glucose log review) and 1 month in-person. HbA1c will be rechecked at 3 months. If hypoglycemic episodes (capillary glucose <70 mg/dL with symptoms) occur, insulin dose is reduced by 2–4 units. By 6 months, her HbA1c reaches 7.2% with insulin glargine 14 units nightly (lower than the standard dose would have been, owing to the synergistic empagliflozin effect).

Top 10 Empagliflozin Interactions by Severity

• Insulin (Major): Additive hypoglycemic effect; reduce insulin dose 10–25% at empagliflozin initiation; monitor home glucose four times daily; assess for symptomatic hypoglycemia.
• Sulfonylureas—glyburide, glipizide, glimepiride (Major): Increased hypoglycemia risk; reduce sulfonylurea dose 25–50% or consider deprescribing; home glucose monitoring before meals and bedtime; HbA1c recheck at 3 months.
• Diuretics—loop (furosemide, bumetanide, torsemide) and thiazide (hydrochlorothiazide, chlorthalidone) (Moderate): Additive osmotic and pharmacological diuresis; risk of volume depletion, prerenal AKI, hypernatremia, orthostatic hypotension; monitor orthostatic vitals; baseline and serial (1–2 weeks, then quarterly) serum creatinine, eGFR, sodium; may require diuretic dose reduction.
• Lithium (Moderate): SGLT2 inhibition may alter sodium-lithium exchange; unpredictable effect on lithium clearance; baseline and serial (1 week post-initiation, then biweekly × 8 weeks) lithium levels targeting 0.6–1.2 mEq/L; maintain consistent sodium and fluid intake; consider alternative mood stabilizer if available.
• ACE Inhibitors—lisinopril, enalapril, ramipril (Moderate): Combined effect on glomerular filtration and sodium handling; risk of hyperkalemia and prerenal AKI if volume-depleted; baseline and quarterly potassium and creatinine; avoid if K+ >5.5 mEq/L or eGFR <20 mL/min/1.73m².
• Angiotensin Receptor Blockers—losartan, valsartan, irbesartan (Moderate): Same mechanism as ACE inhibitors; risk of hyperkalemia and prerenal AKI; baseline and quarterly potassium and creatinine monitoring.
• NSAIDs—ibuprofen, naproxen, meloxicam, indomethacin (Moderate): Reduced glomerular filtration and tubular secretion; additive risk of prerenal AKI, volume depletion, acute interstitial nephritis; avoid NSAIDs in patients with eGFR <30 mL/min/1.73m² or those on concurrent ACE-I/ARB; if NSAID required, lowest dose for shortest duration with close renal monitoring.
• Meglitinides—repaglinide, nateglinide (Moderate): Glucose-dependent insulin secretagogues; additive hypoglycemic effect similar to sulfonylureas but with shorter duration; consider deprescribing in favor of metformin; if continued, monitor home glucose and assess HbA1c at 3 months.
• Antidiabetic Agents—GLP-1 Receptor Agonists (exenatide, semaglutide, dulaglutide) (Minor-to-Moderate): Additive glucose-lowering effect; no major pharmacokinetic interaction; risk of gastrointestinal side effects and dehydration from GLP-1 agonist nausea; adequate hydration counseling; no dose adjustment typically required but monitor HbA1c.
• Corticosteroids—prednisone, dexamethasone (Moderate): Hyperglycemic effect of steroids antagonizes empagliflozin; higher empagliflozin doses or additional glucose-lowering agents may be needed; monitor home glucose more frequently during steroid courses; assess HbA1c after steroid discontinuation.

Specific Monitoring Parameters and Lab Intervals

Baseline (Before Empagliflozin Initiation):

• Serum creatinine, eGFR (using CKD-EPI 2021 equation)
• Fasting or random glucose, HbA1c
• Electrolytes: sodium, potassium, chloride, bicarbonate
• Urinalysis (assess for glucosuria, proteinuria, signs of UTI—empagliflozin increases UTI risk)
• Blood pressure (supine and standing)
• Body weight

1–2 Weeks Post-Initiation:

• Serum creatinine, eGFR, electrolytes
• Phone call or office visit to assess for hypoglycemia symptoms, polyuria, thirst, volume depletion signs
• Orthostatic vital signs

Monthly (First 3 Months):

• Home glucose log review (if on insulin or sulfonylureas)
• Blood pressure and orthostatic vitals
• Assess for genital mycotic infections, urinary symptoms

3 Months:

• Repeat fasting glucose, HbA1c
• Serum creatinine, eGFR, electrolytes
• Adjust glucose-lowering agent doses based on HbA1c and hypoglycemia frequency

Quarterly (Every 3 Months) Thereafter:

• Serum creatinine, eGFR, electrolytes (if on ACE-I/ARB or diuretics)
• Annual HbA1c reassessment minimum

For Patients on Lithium:

• Baseline lithium level (trough, 5 days after last dose adjustment)
• 1 week post-empagliflozin initiation: lithium level, serum creatinine, electrolytes
• Biweekly lithium levels for 8 weeks, then monthly × 4 months, then quarterly if stable

What Patients Should Tell Their Doctor

Patients initiating empagliflozin should inform their healthcare provider of the following:

• All current diabetes medications: Insulin type and daily dose, sulfonylurea or meglitinide use, other GLP-1 agonists or DPP-4 inhibitors. Do not stop or reduce doses without explicit instruction.
• Diuretic use: Loop, thiazide, or potassium-sparing diuretics taken for heart failure, hypertension, or edema. Doses may need adjustment.
• Lithium or other mood stabilizers: Critical for renal and electrolyte management; alternatives may be safer.
• NSAIDs: Over-the-counter ibuprofen or naproxen use; these increase kidney injury risk with empagliflozin.
• ACE inhibitors or ARBs: Essential for proper monitoring of potassium and renal function.
• History of diabetic ketoacidosis (DKA) or recurrent urinary tract infections: SGLT2 inhibitors carry a small but real risk of euglycemic DKA and increase UTI/genital infection rates.
• Pregnancy or breastfeeding plans: SGLT2 inhibitors should generally be avoided in pregnancy.
• History of heart failure, severe volume depletion, or orthostatic hypotension: Close monitoring and possible dose adjustment required.

Patients should also report:

• Symptoms of hypoglycemia: tremor, palpitations, sweating, dizziness, confusion, hunger
• Symptoms of volume depletion: dizziness on standing, fainting, severe thirst, unusual dry mouth
• Symptoms of urinary tract infection or genital infection: dysuria, frequency, urgency, genital itching or discharge
• Unusual fatigue, nausea, or abdominal pain (concerning for euglycemic DKA, though rare)

Key Takeaways

• Insulin and sulfonylureas require dose reduction of 10–50% when empagliflozin is initiated due to compounded hypoglycemia risk; home glucose monitoring should increase to four times daily during the first 2 weeks, and HbA1c reassessment occurs at 3 months.
• Diuretics (loop and thiazide) combined with empagliflozin create compounded osmotic and pharmacological diuresis, raising risk of prerenal acute kidney injury, hypernatremia, and orthostatic hypotension; baseline and serial renal function and electrolyte monitoring every 1–2 weeks initially, then quarterly, is essential.
• Lithium levels become unpredictable when empagliflozin is started due to altered sodium-lithium exchange; baseline and frequent lithium level monitoring (biweekly for 8 weeks) is mandatory; consider switching to alternative mood stabilizers when possible.
• ACE inhibitors and ARBs do not have formal FDA contraindications with empagliflozin but increase hyperkalemia and prerenal AKI risk, particularly in volume-depleted patients; potassium and creatinine should be monitored at baseline and quarterly.
• NSAIDs, corticosteroids, and meglitinides require individualized risk-benefit assessment and close clinical monitoring; NSAIDs should be avoided if possible, corticosteroid-induced hyperglycemia may require additional antidiabetic therapy, and meglitinides may be candidates for deprescribing in favor of metformin.

Sources

• FDA Drug Labeling via OpenFDA (open.fda.gov) — Empagliflozin (Jardiance) prescribing information and labeling updates
• Empagliflozin FDA Label: FDA Center for Drug Evaluation and Research Database
• National Kidney Foundation: Chronic Kidney Disease and SGLT2 Inhibitors
• American Diabetes Association Standards of Care: Diabetes Care journal — SGLT2 inhibitor positioning in type 2 diabetes management
• PubMed: SGLT2 inhibitors and hypoglycemia in insulin-treated diabetes — search terms: "empagliflozin hypoglycemia insulin"
• PubMed: SGLT2 inhibitors volume depletion diuretics — search terms: "SGLT2 inhibitor diuretic interaction"
• Lithium and SGLT2 Inhibitors: PubMed Central — search terms: "lithium SGLT2 inhibitor clearance"
• Heart Failure Society of America: SGLT2 Inhibitors in Heart Failure
• NIH National Library of Medicine: MedlinePlus Drug Information — Empagliflozin

Get Your Complete Drug Interaction Report

Empagliflozin's interaction profile is complex and clinically significant, particularly in patients on insulin, sulfonylureas, diuretics, or lithium. The key to safe use is proactive screening, patient education, and regular monitoring of glucose, renal function, volume status, and electrolytes. If you or a family member is taking empagliflozin alongside any of the medications discussed here, don't rely on memory alone. Visit checkdruginteractions.com to upload your complete medication list and receive a personalized, FDA-based interaction report. Our comprehensive database checks over 250,000 FDA drug labels to identify every potential interaction—major, moderate, and minor—giving you and your healthcare team the confidence to make informed, safe medication decisions. Check your medications today.